1,251 reports of this reaction
1.4% of all GEMCITABINE HYDROCHLORIDE reports
#19 most reported adverse reaction
PANCYTOPENIA is the #19 most commonly reported adverse reaction for GEMCITABINE HYDROCHLORIDE, manufactured by Armas Pharmaceuticals Inc.. There are 1,251 FDA adverse event reports linking GEMCITABINE HYDROCHLORIDE to PANCYTOPENIA. This represents approximately 1.4% of all 92,220 adverse event reports for this drug.
Patients taking GEMCITABINE HYDROCHLORIDE who experience pancytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PANCYTOPENIA is a less commonly reported adverse event for GEMCITABINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to pancytopenia, the following adverse reactions have been reported for GEMCITABINE HYDROCHLORIDE:
The following drugs have also been linked to pancytopenia in FDA adverse event reports:
PANCYTOPENIA has been reported as an adverse event in 1,251 FDA reports for GEMCITABINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PANCYTOPENIA accounts for approximately 1.4% of all adverse event reports for GEMCITABINE HYDROCHLORIDE, making it a notable side effect.
If you experience pancytopenia while taking GEMCITABINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.